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http://dx.doi.org/10.1016/j.jmii.2012Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is characterized by peri-
odic fever, cutaneous rash, conjunctivitis, lymphadenopathy, abdominal pain, myalgia, and
arthralgia. It is a rare autosomal dominant disease and strongly associated with heterozygous
mutations in the tumor necrosis factor (TNF) receptor super family 1A (TNFRSF1A) gene. It is
believed to be more common in Western countries than in Asian countries. Here, we present
the case of a 14-year-old girl with periodic fever and abdominal pain with elevation of inflam-
matory markers for 2 years. After extensive work-up of infectious etiology with negative
results, the diagnosis of TRAPS was made although no gene mutations were identified in the
TNFRSF1A gene, MVK gene, and NALP3/CIAS1 gene. She had partial clinical response to corti-
costeroids and immunomodulatory agents. However, the treatment response to TNF-a inhibitor
etanercept was dramatic. She has remained symptom free under regular weekly to biweeklyof Pediatrics, National Taiwan University Hospital, Number 7, Chung-Shan South Road, Taipei 100,
tw (B.-L. Chiang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.07.003
Abdominal pain in TRAPS 551etanercept treatment for 2 years. We also reviewed the related literature and summarized the
data of 10 Asian cases of TRAPS.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hereditary periodic (recurrent) fever syndromes are
a group of autoinflammatory diseases characterized by
recurrent episodes of unprovoked inflammation without
high-titer autoantibodies or autoreactive T cells. Seven
diseases exhibit Mendelian patterns of inheritance with
identified single gene defects.1 They include familial
Mediterranean fever (FMF), tumor necrosis factor
receptor-associated periodic syndrome (TRAPS), pyogenic
sterile arthritis, pyoderma gangrenosum and acne (PAPA),
hypergammaglobulinemia D with periodic fever syndrome
(HIDS) and three overlapping conditions, the cryopyr-
inopathies, with common cryopyrin abnormalities: familial
cold autoinflammatory syndrome (FCAS); Muckle-Wells
syndrome (MWS); and neonatal-onset multisystem inflam-
matory disease (NOMID), also known as chronic infantile
neurologic cutaneous articular syndrome (CINCA). Hered-
itary periodic fevers are characterized by recurrent flares
of systemic inflammation presenting as sudden episodes of
fever associated with a dramatic elevation of acute phase
reactants and a number of clinical manifestations, such as
rash, serositis (peritonitis, pleuritis), lymphadenopathy,
and arthritis.2 Disease flares are usually separated by
symptom-free intervals of variable duration, character-
ized by complete well-being, normal growth, and
complete normalization of acute phase reactants. The
clinical spectrum of these disorders is also extremely
variable.
TRAPS is characterized by periodic fever (duration of
more than1week),migratory cutaneous rash, conjunctivitis,
periorbital edema, lymphadenopathy, abdominal pain,
myalgia, arthralgia, and serositis. It is an autosomal domi-
nant disease that is related to heterozygous mutations in the
tumor necrosis factor (TNF) receptor super family 1A
(TNFRSF1A) gene encoding TNF receptor type 1 (TNFR1).
Levels of acute-phase reactants are elevated during attacks
and also during asymptomatic periods. TRAPS is the second
most common disease among hereditary periodic fever
syndromes following FMF. Although people of any ethnicity
may be affected, there have been few reports to date with
regards to patients fromAsia. Here,wepresented the case of
a 14-year-old Asian girl with recurrent fever and abdominal
pain for 2 years who was finally diagnosed with TRAPS, and
had good response to etanercept, an anti-TNF-a agent.
Case report
A 14-year-old girl presented with ten periodic episodes of
severe periumbilical abdominal pain with fever for nearly
2 years. The abdominal pain was not related tomenstruation
and was not associated with vomiting. The episodes lasted
for 10e14 days and recurred at intervals of 1 month. Thefever had a characteristic feature of the body temperature
rising to 39C or higher on a daily basis. Physical examination
revealed diffuse tenderness and left rebound pain without
hepatosplenomegaly. None of the episodes were associated
with lymphadenopathy, skin rash, arthritis, arthralgia,
conjunctivitis, or periorbital edema. She led a normal life
during symptom-free days and had normal growth, and she
did not have a family history of similar conditions. She had
been diagnosed with acute abdomen or intra-abdominal
infections without proven pathogens of bacteria, tubercu-
losis or parasites. Diagnostic laparoscopy was conducted
several times and revealed only ascites. Abdominal
computed tomography (CT) showed para-aortic and mesen-
teric lymphadenopathies. There was a marked acute phase
response indicated by elevation of white blood cell (WBC)
count (15,680/ml), C-reactive protein (CRP; 16.98 mg/dl),
erythrocyte sedimentation rate (43 mm/hour), C3 (166 mg/
dl), and C4 (32.9 mg/dl). Other laboratory investigations
showed elevated serum TNF-a levels (61.7 pg/ml), negative
antinuclear antibodies and normal serum immunoglobulin D
concentrations. Gallium scan showed diffusely increased
tracer uptake in the bone marrow of vertebral bones,
however bone marrow study revealed normal findings.
Repeated panendoscopy, small intestinal endoscopy, and
colon fibroscopy revealed gastric, duodenal, small intes-
tinal, and colon ulcerations. The pathologic findings of colon
biopsies showed inflammatory infiltrates with IgMþ plasma
cells and diffuse CD8þ cytotoxic T cells; however, there was
an absence of CD4þ T-helper cells. The epithelium was
focally destructed by CD8þ cytotoxic T cells.
Based on the patient’s clinical history, TRAPS was highly
suspected. After informed consent was obtained, sequence
sequencing of the TNFRSF1A gene, MVK gene (for hyper-IgD
syndrome), and NALP3/CIAS1 gene (for familial cold-
autoinflammatory syndrome or MWS) were performed.
However, no mutations were found in the promoter or
coding regions of these genes. She was treated with
nonsteroidal anti-inflammatory drugs (NSAIDs), colchicines
(0.5 mg twice per day); however, the response was poor.
The abdominal pain and fever came under control after
using a short course of intravenous methylprednisolone
(2 mg/kg/day) for 5 days. The episodic clinical symptoms
were only partially controlled by immunomodulatory
drugs (azathioprine 1.6 mg/kg/day and mesalamine
30 mg/kg/day). However, the abdominal pain and fever had
a dramatic response to a TNF-a inhibitor, etanercept
(0.4 mg/kg/dose biweekly) monotherapy. Normalization of
the inflammatory parameters such as WBC and CRP were
found after etanercept usage. She has remained symptom
free under regular weekly to biweekly etanercept therapy
for 2 years. It is worth mentioning that severe abdominal
pain without fever rapidly occurred after missing one dose
of etanercept during these 2 years of treatment.
Table 1 Primers used for PCR sequencing of the TNFRSF1A gene, and RT-PCR of MVK gene, and NALP3/CIAS1 gene
Gene Forward primer Backward primer
MVK CCAGGAGCCATGTTGTCAGA GGTGTTGGTCAGCAGGAT
CACGAAGTTGTGCCTACC TGGCCAGCACAGAGTCGAAC
NALP3 AGCCACGCTAATGATCGACT TATGCCAGTCAGTGCAGAGC
GATCGTGAGAAAACCCTCCA CTTCCTCCTTGGGCATGTTA
GCTTCGACATCTCCTTGGTC TCTGGCTGGAGGTCAGAAGT
AACTGTCATCGGGTGGAGTC ATGGATCGCAGCTCTCTC
TNFRSF1A GGCTTATTGCCCCTTGGTGTT TGGCTGAGGTTAGGACCTGCA
GAATGTTTCACTGAGGAAGGAC CACCAAAACACACACCTTCCTG
GGACACTGCATGGATGTGAGT CAGTAGGACCCTGAGCACTCT
GATGTCCAACAATCTGTGTGGT TCACCTCCCTCCACACATGTC
TGAGGCATGTGACCACAAGTC CGCCTCTCGTGGTCCCCTCT
TTTCTCCCGCGGCTGGAGACGA CGCAGGCAGCTGAGAAAAGCT
552 Y.-J. Chen et al.Sequencing of the TNFRSF1A gene
The genomic polymerase chain reaction (PCR) was per-
formed using the HotStarTaq Plus PCR system (Qiagen
GmbH, Hilden, Germany). Genomic DNA was amplified
using the sense and antisense primers (Table 1) according to
the manufacturer’s protocol. PCR cycling was performed in
a thermocycler as follows: 5 minutes of initial denaturation
at 94C, followed by 50 thermal cycles (denaturation for 30
seconds at 94C, annealing for 1 minute at 60C, and
extension for 1 minute at 72C), completed with 2 minutes
of incubation at 72C. The PCR product was analyzed by
1.5% agarose gel electrophoresis. DNA sequencing was
performed on both strands using BigDye Terminator v3.1
Cycle Sequencing Kit and 3730xl DNA Analyzer (Applied
Biosystems, Foster City, CA, USA).
Sequencing of the MVK and NALP3/CIAS1 genes
Total RNA was isolated from peripheral blood mononuclear
cells with TRIzolR (Life Tech, Carlsbad, CA, USA). Reverse
mRNA transcription followed by polymerase chain reaction
(RT-PCR) was performed as previously described (Lee et al.
2005).3 Briefly, 1 mg of RNA in a total volume of 20 ml was
reverse-transcribed into cDNA using oligo-dT primers (Invi-
trogen, Carlsbad, CA, USA) and superscript RNaseH-reverse
transcriptase (Qiagen, Chatsworth, CA, USA), and then
amplified using 1 ml of cDNA in a total volume of 20 ml con-
taining 0.5 U High Fidelity Taq DNA polymerase (Invitrogen),
1.875 mmol/L MgSO4, 200 mmol/L dNTP, and 500 nmol/L of
one pair of oligonucleotide primers selected to cover the
indicated coding region of the candidate genes (Table 1). The
mutations identified from the cDNA were confirmed by
sequence analysis of genomic DNA. Sequencing was per-
formedusing theBigDyeTerminator kit andanABI PRISM3100
DNA Sequencer (Applied Biosystems, Foster City, CA, USA).
Discussion
In our case, the clinical features were compatible with
TRAPS, including periodic attacks of fever lasting at least 1
week, abdominal pain, the presence of an acute-phase
response when symptomatic, and a poor response tocolchicines. Our patient lacked symptoms such as skin rash,
conjunctivitis, arthralgia, or myalgia. Etanercept resulted
in disease remission and prevented disease recurrence.
Furthermore, discontinuing the drug caused disease flare-
ups. The incidence of TRAPS varies among different ethnic
groups. Most of the reported cases of TRAPS have involved
individuals of northern European ancestry including Irish,
Scottish, Finnish, French, and Dutch populations, and
families of other ethnic groups such as Jewish, and Puerto-
Rican have also been described. Reports involving Asian
people are quite rare, and most reported cases have
involved individuals from Japan. To the best of our knowl-
edge, this is the first case reported in Taiwan.
No mutations in the TNFRSF1A gene, MVK gene (for HIDS)
or NALP3/CIAS1 gene (for FCAS, MWS, NOMID/CINCA) were
found in our patient. TRAPS has been associated with at
least 84 different mutations of the TNF receptor super-
family 1A gene (TNFRSF1A) encoding for the trans-
membrane TNFR1 protein, also known as p55 TNFR
(INFEVERS TRAPS database: http://fmf.igh.cnrs.fr/
infevers). TNFRSF1A mutations have been identified in
a minority of patients, and mainly in association with
a positive family history. In two families and in 90 sporadic
cases that presented with TRAPS-like symptoms, Aksenti-
jevich et al.4 did not identify any TNFRSF1A mutations.
Another large study by Aganna et al.5 showed that only four
of 176 patients with sporadic (non-familial) TRAPS-like
symptoms were found to have TNFRSF1A mutations. Since
TNFRSF1A mutations can not be identified in a proportion of
patients with TRAPS-like phenotype, further studies to rule
out the involvement in the pathogenesis of TRAPS of some
of the genes known to regulate TNFR1 shedding, TNF-
induced nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) signal and transcription are
needed. Unidentified genes remain to be investigated by
a candidate gene approach in the TNF pathway or by
applying the genome-wide function-free sequencing
approach.6
The pathogenic mechanisms underlying TRAPS remain
unresolved. Activation of TNFR1 by TNF causes cleavage
and shedding of the extracellular part of TNFR1 from the
cell surface into the circulation. The secreted form of TNF
receptor acts as a natural inhibitor of TNF-a. TNFRSF1A
mutations were formerly thought to cause inflammation by
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Abdominal pain in TRAPS 553reduced TNFR1 shedding. However, defects in the shedding
of TNFR1 by measuring serum soluble TNFR1 concentrations
have been found to be inconsistent among patients.5
TNFRSF1A mutations also affect receptor folding and traf-
ficking. TNFR1 mutant proteins are retained and accumu-
late in the endoplasmic reticulum, activating mitogen-
activated protein kinase (MAP) kinases and mitochondrial
reactive oxygen species, resulting in constitutive inflam-
mation through the secretion of proinflammatory cytokines
such as Interleukin-1 (IL-1) and Interleukin-6 (IL-6).7
We summarized the clinical presentations, gene muta-
tions, laboratory data, and treatment in 11 TRAPS cases
including our patient from eastern Asia in Table 2.
The onset age was typically young, with four cases in
infancy and four in early childhood. The symptoms of the
Japanese patients were milder than those reported in the
Caucasian patients.8 Chest pain was not observed in these
patients. Abdominal pain is a hallmark of TRAPS, and is
reported to occur in more than 90% of TRAPS patients.
However, it was only reported in four of 11 (36.4%) of the
Asian patients from our review (Table 2). Abdominal pain
may reflect inflammation within the peritoneal cavity or
the musculature of the abdominal wall. Signs of an acute
abdomen often result in laparotomy and appendectomy, as
in our patient. Serum TNF-a was low in two of 11 (18%)
cases, and decreased sTNFRSF1A was seen in two of 11
(18%) patients.
As for the treatment for TRAPS, fever episodes usually
respond to NSAIDs or corticosteroid treatment.2 NSAIDs are
generally unable to resolve musculoskeletal and abdominal
symptoms. However, because of the possible long duration
of fever attacks and the tendency to a chronic course,
patients may become steroid-dependent. The use of other
immunomodulatory drugs such as azathioprine, cyclo-
sporin, thalidomide, cyclophosphamide, chlorambucil,
intravenous immunoglobulin, dapsone, and methotrexate
have been reported to be ineffective in TRAPS patients with
regard to reducing the frequency and the intensity of the
inflammatory episodes or in preventing the development of
amyloidosis.9 The hyperinflammatory response in TRAPS
creates a rationale for TNF blockade in the treatment of
TRAPS. Many reports have proved that infliximab,
a chimeric monoclonal antibody that binds to human TNF-a,
can induce the inflammatory attack,10 while etanercept,
a dimeric recombinant fusion protein of soluble TNFR linked
by the Fc-fragment of IgG1, decreases the intensity and
duration of inflammatory episodes.11 In some TRAPS
patients resistant to TNF-a inhibitor therapy, IL-1 receptor
antagonist (anakinra) has been shown to control recurrent
fever and prevent recurrence.9,12
The most devastating complication that clinicians should
be concerned with in this kind of patient is reactive
amyloidosis, which occurs in all kinds of hereditary periodic
fever syndromes. The continuous elevation of serum
amyloid A (SAA), one of the acute phase serum proteins,
results in the development of AA systemic amyloidosis.
The accumulation of AA amyloid fibrils in the extracellular
spaces of various organs and tissues, most notably the
kidneys (>90%), liver and spleen, and gastrointestinal
involvement (20%), leads to organ failure in the middle age
of life.13 An estimated 14e25% of TRAPS patients develop
reactive amyloidosis, but this has not been seen in Asian
554 Y.-J. Chen et al.cases (Table 2). It has been shown that certain TNFRSF1A
gene mutations and duration and severity of inflammation
confer increased risks for the development of AA amyloid-
osis; however, other genetic or environmental factors may
also modulate the risk.5 Etanercept has been shown to
reduce not only the clinical symptoms and normalization of
inflammatory parameters, but also SAA. In some reports,
etanercept further reversed nephrotic syndrome.14
In conclusion, although periodic fever and abdominal
pain are characteristic of TRAPS, there is usually a delay of
diagnosis due to the extreme rarity of these disorders,
especially in Asians. TRAPS should be considered in the
differential diagnosis of recurrent fever cases. Most
sporadic TRAPS cases have no TNFRSF1A gene mutations.
Genetic heterogeneity with other genes effect exists in
TRAPS patients. Regular etanercept usage can achieve
resolution of symptoms and prevent systemic amyloidosis,
and is recommended as the preferred treatment rather than
corticosteroids. Although none of the patients in our review
of Asian cases developed amyloidosis, we suggest continu-
ously monitoring urinalysis and serum amyloid A concen-
trations during long-term follow-up of these patients.
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